WO2004022098A1 - Oxygen-enriched water, treated within a magnetic field and heavy water - Google Patents
Oxygen-enriched water, treated within a magnetic field and heavy water Download PDFInfo
- Publication number
- WO2004022098A1 WO2004022098A1 PCT/HU2002/000085 HU0200085W WO2004022098A1 WO 2004022098 A1 WO2004022098 A1 WO 2004022098A1 HU 0200085 W HU0200085 W HU 0200085W WO 2004022098 A1 WO2004022098 A1 WO 2004022098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- magnetic field
- enriched
- heavy
- oxygen
- Prior art date
Links
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 title claims abstract description 149
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 67
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000001301 oxygen Substances 0.000 title claims abstract description 44
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 44
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229910001882 dioxygen Inorganic materials 0.000 claims abstract description 40
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract description 35
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000030507 AIDS Diseases 0.000 claims abstract description 9
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000000155 isotopic effect Effects 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract 3
- 239000000047 product Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 claims description 10
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 claims description 10
- 239000012263 liquid product Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 5
- 229940127554 medical product Drugs 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 235000019568 aromas Nutrition 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 230000002045 lasting effect Effects 0.000 claims description 2
- 229910000859 α-Fe Inorganic materials 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 239000008155 medical solution Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 16
- 239000001257 hydrogen Substances 0.000 abstract description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 20
- 239000003651 drinking water Substances 0.000 description 16
- 235000020188 drinking water Nutrition 0.000 description 16
- 239000000126 substance Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/50—Preservation of non-alcoholic beverages by irradiation or electric treatment without heating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/48—Treatment of water, waste water, or sewage with magnetic or electric fields
- C02F1/481—Treatment of water, waste water, or sewage with magnetic or electric fields using permanent magnets
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/727—Treatment of water, waste water, or sewage by oxidation using pure oxygen or oxygen rich gas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/005—Systems or processes based on supernatural or anthroposophic principles, cosmic or terrestrial radiation, geomancy or rhabdomancy
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
Definitions
- Goldauqa oxygen-enriched within a magnetic field, magnetically treated water and heavy-water. /0,1-120 ppm deuterium content/,food-bio and pharmaceutical liquid product, suitable to prevent and cure cancerous and AIDS diseases and apparatus for preparing these product.
- the purpose of the invention, Goldaqua, oxygen-enrichment within a magnetic field production method (Figure 1); is to ensure enhanced physiological results to liquids and other purpose of the invention, we supply in the heavy-water reduced hydrogen energy level, with magnetic energy. According to scientific observations the molecules in liquids, much like in gases, are randomly located.
- the basics of this invention is, that through using direct oxygen-enriched water within a magnetic field, in the heavy-water 10, 1-120 ppm deuterium content/and using efficiency Gidler- Sulphide type or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, heavy- water manufacturing process,for the producing healthy products.
- my invention is to improved biotechnology with original magnetic apparatus ( Figure 1), than earlier used magnetic and oxygen enriched equipment and treatments.
- This invention opening on the outspreaded and efficiency heavy- water manufacturing method, than in the HU.patent number 218574 description writing down fluid hydrogen with distillation process, for the cancer therapy.
- US.patent number 5,009,791 description writing down have simple magnetic treatment and magnetic apparatus, dont increased energy level with permitted oxygen gas in to the magnetic field.
- WO 95/18545 patent description used normal heavy-water was small influences and don't supplied reduced energy of hydrogen level.
- the goal of the invention is to develop an original approach (Figure l)to obtain final products that have better physiological result than previous products.
- the other purpose of inventing a heavy-water depleted hydrogen bond formation is supplying with magnetic energy and plus oxygen content. Furthermore according to the status of technology this invention is to improve heavy-water quality, with oxygen enrichment within a magnetic field process, for the health of the individual.
- the subject of invention is preparing food-medical products with medical oxygen gas-enriched magnetically treated water and heavy water.
- procedure water is direct enriched with oxygen while passing through a magnet ( Figure 1), the mixture gained is used in producing nonalcoholic beverages within standard procedures in making bio-medical products.
- the purpose of invention is realized a long term guaranteed lasting of the magnetic-energy enriched, additive free liquid and food-medical biotechnology.
- the mechanism of water exercised on the living body be greatly improved.
- the biotechnology of medical oxygen gas direct enrichment within a magnetic field, result in structural order energy level increase.
- the purpose of invention through a production method, in drawing ( Figure 1) is to ensure enhanced physiological results to products.
- the basis of invention is the recognition that when water and heavy-water with the efficiency Gidler-Sulphide type or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, heavy-water manufacturing process is enriched with medical oxygen gas within a magnetic field.
- the magnetic cylinder 4 strength of the magnetic field is optimal level is 1000-1500 gauss.
- the type of magnet used is Ferrite magnet.
- Medical oxygen gas is an extremely recant gas which reacts with a number of materials/for instance, hydrogen and organic materials/.
- the electromagnetic reactions present in a living body are of fundamental importance.
- the dielectric constant of a liquid, medical oxygen gas-enriched while flow through a magnetic field changes.
- the dielectric constant bears a fundamental significance on life because the internal and external environment of bodily functions has always been water.
- the subject of invention, an important example of this reaction is the medical oxygen gas enrichment of water within a magnetic field, which results in a colloid state and stability.
- One of the effects of magnetic field on bio-system is that through water.
- the dielectric constant changes.
- the dielectric constant of healthy cell liquid is 80 ⁇ r
- cancerous and HIV-1 cell liquid is 5 ⁇ r .
- the normal heavy-water, magnetically treated heavy-water enriched with medical oxygen gas while passing through a magnetic field was used in preparing a nutritional solution capable of sustaining added to the water amino acid, vitamins, salts.
- a nutritional solution capable of sustaining added to the water amino acid, vitamins, salts.
- mice normal drinking water we gave the mice normal drinking water.
- Group C In the laboratory tests series according to the procedure, we transplanted tumors into the mice.
- mice The body/tumor mass of the mice was similar to that of starting treatment of a human with a body mass of 80 kg and tumor mass of 2 kg. /
- the daily dose can be of 2-4 liter. Since the magnetically treated heavy- water/30 ppm deuterium content/, enriched with medical oxygen gas while run through a magnetic field does not contain minerals, it has to be given additives before human consumption.
- the ideal salt concentration per liter Na: 90 mg, K: 150 mg, Ca: 130 mg, Mg: 70 mg, Cl: 500 mg.
- the magnetically treated heavy- water /30 ppm deuterium content with " medical oxygen gas enriched while passing through a magnetic field enhances the influence on the body and stops the multiplication of cancerous cells, we supply reduced energy level of hydrogen, with magnetic bioenergy.
- the furthermore basic of this invention is the understanding cancer comparison with AIDS/HIN-
- Vitamin contain/litre: lOOmg of sodium, 150mg of calcium, and 80mg of magnesium, 500mg of chlorine, and 150mg of potassium.
- the subject of invention importance of enriching magnetically treated heavy water /30 ppm deuterium content/ with medical oxygen gas, within a magnetic field.
- Normal drinldng water is enriched with medical oxygen gas at a oxygen-enriched apparatus
- FIG. 1 inflow section 1 as a valve is opened, drinking water is flown through a magnetic apparatus and is directly enriched with oxygen gas in to the direct connection to the magnet 2, the magnet 3 increase oxygen concentration level, water is flown through a magnetic cylinder 4 and blending with oxygen, water out flow in the out flow section 5.
- the optimum amount medical oxygen gas issued/enriched/ is 10-20mg/liter.
- Normal drinking water made according to the methods explained in example 1 can further be used advantageously to produce soft drinks by adding drink concentrates.
- Composition 50g/li ter sugar,5 volume% orange juice, 10-20mg/liter medical oxygen gas, lg/liter citric acid,500mg/liter natural aromas.
- Basic substance heavy-water /0, 1-111 ppm deuterium content/manufacturing by isotopic exchange between water and H 2 S occurring upon temperatures difference or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, after direct enriched with medical oxygen gas 10-20mg/liter while passing through a magnetic field.
- the resulting magnetically treated heavy water has been transformed into a medical liquid within the magnetic field and the outflow liquid bottling in the bottles.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hydrology & Water Resources (AREA)
- Organic Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Environmental & Geological Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Goldaqua, oxygen-enriched within a magnetic field magnetically treated water and heavy water/0,1-120 ppm deuterium content/, enriched with medical oxygen gas 10-20 mg/liter, while passing through a magnetic field, biomedical liquids products, suitable to prevent and cure cancerous and AIDS diseases. According to the status of technology, the method through with directly oxygen enrichment within a magnetic field process, we supplied energy of hydrogen with magnetic energy with special oxygen enriched apparatus (Figure 1) that have a parts : inflow section/1/,direct connection in to the magnet/2/, magnet/3/, magnetic cilynder/4/, outflow section/5/. We ensure an completely of providing oxygen within a magnetic field and supply with magnetic bioenergy the reduced hydrogen energy level in the heavy-water, of producing by isotopic exchange between water and H2S occuring upon temperatures difference: water and/or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius. Aqueous solution having a deuterium content 0,1-120 ppm. With the biotechnology process (Figure 1) produced liquids, human body and thus help it prevent and/or fight cancer and AIDS(HIV-1).
Description
DESCRIPTION TITLE OF THE INVENTION:
OXYGEN-ENRICHED WATER, TREATED WITHIN A MAGNETIC FIELD AND HEAVY WATER
BACKGROUND OF INVENTION
Goldauqa, oxygen-enriched within a magnetic field, magnetically treated water and heavy-water. /0,1-120 ppm deuterium content/,food-bio and pharmaceutical liquid product, suitable to prevent and cure cancerous and AIDS diseases and apparatus for preparing these product. The purpose of the invention, Goldaqua, oxygen-enrichment within a magnetic field production method (Figure 1); is to ensure enhanced physiological results to liquids and other purpose of the invention, we supply in the heavy-water reduced hydrogen energy level, with magnetic energy. According to scientific observations the molecules in liquids, much like in gases, are randomly located. The basics of this invention is, that through using direct oxygen-enriched water within a magnetic field, in the heavy-water 10, 1-120 ppm deuterium content/and using efficiency Gidler- Sulphide type or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, heavy- water manufacturing process,for the producing healthy products.We provide the body an optimal amount of oxygen and we supply reduced energy of hydrogen, with magnetic energy and create that has an orderly structure liquid products with Goldaqua, oxygen enriched apparatus, that have a parts: inflow section, direct connection in to the magnet, magnet, magnetic cylinder, outflow section. According to the status of manufacturing technology, my invention is to improved biotechnology with original magnetic apparatus (Figure 1), than earlier used magnetic and oxygen enriched equipment and treatments. This invention opening on the outspreaded and efficiency heavy- water manufacturing method, than in the HU.patent number 218574 description writing down fluid hydrogen with distillation process, for the cancer therapy.In the agricultural purpose process US.patent number 5,009,791 description writing down have simple magnetic treatment and magnetic apparatus, dont increased energy level with permitted oxygen gas in to the magnetic field.In the other U.S.patent number,5,855,921 description and PCTJHU 92/00036, WO 95/18545 patent description used normal heavy-water was small influences and don't supplied reduced energy of hydrogen level. According to scientific observation the molecules in liquid- much like in gases-are randomly located. We preparing with (Fig 1) technology specially heavy- water liquid product and using isotopic exchange basic heavy-water manufacturing process, between water and H2S occurring temperature difference or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius.
Narious external factors magnetic field among them/will change the equilibrium concentration of every particular type of clusters depending on their stability, which in turn depends on the energy of hydrogen bonds within them.Up to date only traditional methods were used to treat substances with magnetic field energy and enriching them with oxygen.
Such traditional methods are detailed in the following patent procedures: US 5009791.HU-T- 66475, HU 162455, EP 322544 and the STΝ: CAPLUS AN 1972:492688 on line information package, as well as the equipment developed for treating liquid substances and enriching them with oxygen as detailed in HU187898 patent details and HU-T-71206 patent license detail. The purpose of this invention through production method (Figure 1) is to ensure enhanced physiological result products.In patent description HU 208 084 and WO 93/08794, WO 95/18545 the depleted deuterium water has an disintegrated structure with loosened hydrogen bound and the energy that is lessened this way is not substituted. The status of technology, these methods and liquid products have small contain energy level. The strength of hydrogen ion concentration, increase magnetic energy for heavy-water.The traditional methods are apparent in the fact that these methods don't ensure the enrichment and blending of the substances within the magnetic field and they have a lower energetical efficiency than my invention (Figure 1) and demostrated in the comparative tables 1-5/.
This magnetic technology, the positive properties of the liquid can be improved significantly if we connect (Figure 1) it directly inside the magnetic field.
According to scientific observation the molecules in liquids-much like in gases-are radomly located. We preparing specially heavy-water liquid product and using manufacturing process, with isotopic exchange process. According the procedure, we can supply reduced energy level of hydrogen, with magnetic bioenergy. According to various technologies, the fact that liquid substances can be enriched by oxygen within a magnetic field has not been utilized yet.
The goal of the invention is to develop an original approach (Figure l)to obtain final products that have better physiological result than previous products.
We can ensure this with the technology of entering substances directly inside the magnet. Thus the magneto-biological properties of liquids and gases can be increased. The technology detailed in the invention and the special activation altogether ensures a better efficiency and additional results.
The other purpose of inventing a heavy-water depleted hydrogen bond formation, is supplying with magnetic energy and plus oxygen content. Furthermore according to the status of technology this invention is to improve heavy-water quality, with oxygen enrichment within a magnetic field process, for the health of the individual.
The subject of invention is preparing food-medical products with medical oxygen gas-enriched magnetically treated water and heavy water. In procedure water is direct enriched with oxygen while passing through a magnet (Figure 1), the mixture gained is used in producing nonalcoholic beverages within standard procedures in making bio-medical products.
According to available literature, medical oxygen gas direct enrichment within a magnetic field, magnetically treated water, heavy- water we ensure an optimum of providing oxygen and energy to the human body and thus help it prevent and /or fight cancer and ALDS/ΗIN-1/.
We ensure a quality of the products created with the biotechnology method. Through using beverages that have an orderly molecule structure we provide the body energy, we can prevent and cure cancerous and AIDS/HIN-1/ diseases.
Special oxygen enriched apparatus (Figure 1) for preparing these product, have a part inflow section 1, direct connection in to the magnet 2, magnet 3, magnetic cylinder 4, outflow section 5, that characterization direct connection into the magnet 2 which directly untie bonds through the magnet 3 connecting into the inflow section 1, that have a place between inflow 1 and outflow section 5, and formed magnetic cylinder 4 with thread of screw inflow section 1 between outflow section 5.
The purpose of invention is realized a long term guaranteed lasting of the magnetic-energy enriched, additive free liquid and food-medical biotechnology.
In the resulting composition liquids, water and heavy water with oxygen enrichment within a magnetic field, we ensure an optimum of energy level. Figure 2.
DETAILED DESCRIPTION
It was considered earlier that it is possible to enrich water with oxygen within a magnetic field.
By introducing oxygen to water directly permited within a magnetic field (Figure 1).
The mechanism of water exercised on the living body be greatly improved.
The biotechnology of medical oxygen gas direct enrichment within a magnetic field, result in structural order energy level increase. The purpose of invention through a production method, in drawing (Figure 1) is to ensure enhanced physiological results to products. The basis of invention is the recognition that when water and heavy-water with the efficiency Gidler-Sulphide type or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, heavy-water manufacturing process is enriched with medical oxygen gas within a magnetic field.
Drawing which illustrate embodiment of the invention (Figure 1): inflow section 1, direct connection to the magnet 2,magnet 3, magnetic cylinder 4, outflow section 5.
1.1 In the first steep water is flow in to the inflow section 1.
1.2 Oxygen permitted to the direct connection to the magnet 2.
1.3 In the magnet 3 increase oxygen concentration level. Through the so called "Nenturi" sucking effect we enrich the oxygen content.
1.4 The magnetic cylinder 4 strength of the magnetic field is optimal level is 1000-1500 gauss. The type of magnet used is Ferrite magnet.
1.5 Magnetically treated water, heavy-water out flow, in the out flow section 5.
All living tissue an electron-spin-resonance signal. Medical oxygen gas is an extremely recant gas which reacts with a number of materials/for instance, hydrogen and organic materials/. The electromagnetic reactions present in a living body are of fundamental importance. The dielectric constant of a liquid, medical oxygen gas-enriched while flow through a magnetic field changes.
COMPARATIVE TABLE 1. Dielectric constants: Tap water 81,5 εr > Oxygenated drinking water 82,6 εr, Magnetically treated water 83,1 εr, Oxygen-enriched within a magnetic fields water 85,4 εr > Normal heavy-water 82,4 εr , Magnetically treated oxygen-enriched heavy water 83,3 εr .
According to procedure and products the dielectric constant bears a fundamental significance on life because the internal and external environment of bodily functions has always been water.
The properties of each types of liquid depend much more on their structural organization physical aspects than on their chemical composition. The molecules in water form groups and stay together in a different pattern. Since this continuous dynamics always occurs in a definite order, the distinct structure of water comes about which is the basis of the specific qualities of water.
The reaction between liquid and gas materials greatly depends on this structural pattern. The subject of invention, an important example of this reaction is the medical oxygen gas enrichment of water within a magnetic field, which results in a colloid state and stability. One of the effects of magnetic field on bio-system is that through water.
Living organism from complex magneto-biological systems.'
As a result of the electromagnetic influence in the water enriched with medical oxygen gas while flown through a magnetic field the electrons come into motion according to the"Compton" effect. The dielectric constant changes. The dielectric constant of healthy cell liquid is 80 εr , cancerous and HIV-1 cell liquid is 5 εr.
Since the inner and outer media of vital processes has ever been water, this fact bears a fundamental significance in relation to life.
DESCRIPTION OF THE PREFFERRED EMBODIMENT
Most of the water in the living tissues bears an orderly structure. The reduction of the dielectric constant has fundamental importance in biological functions.
According to the procedure, when water is enriched with medical oxygen gas 10-20mg/liter as it is directly flown through a magnetic field, a dipole system is formed which-beside the increased energy level of hydrogen bounding resembles to crystallites.
A highly organized structure comes into existence; the liquid in this form is effective in living organism. All life functions happen are such liquid base colloids. Magnetic influence can be observed in different organism, cells and molecules as well. It is essential in having oxygen and energy transport and maintaining breathing too. /Metabolism/. In procedure we directly issue medical oxygen gas 10-20mg/liter to water flown through a magnetic field. The biomedical products made this way helps the body to obtain an optimal oxygen and energy supply.
According to the procedure, by making and using medical oxygen gas-enriched, magnetically treated products we resolve replenishing medical oxygen gas, providing energy through using a liquid with orderly structure, preventing and curing cancerous and ALDS/HIN-1/ diseases.
The earliest well-known method of producing heavy water was not treated in the magnetic field and was used through fluid hydrogen with distillation, electrolysis and normal distillation process, chemical reaction of sodium amalgams with natural water process. We preparing heavy- water liquid product and using efficiency manufacturing process, with isotopic exchange process! Based on isotopic exchange between water and H2S occurring upon temperature difference. The installations are of Gidler-Sulphide type and they achieve primarily concentration of deuterium oxide of 4-12% according to the following reaction:
130 Celsius
→
30 Celsius or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius. According the procedure, we supply the reduced energy of hydrogen with magnetic bioenergy.
We use the magnetically treated water and magnetically treated oxygen enriched within a magnetic field heavy-water, is flown through a magnetic field. We increase the antioxidant capacity of water and heavy-water, the medical products improvement, increases the medical properties. The recognition of invention, we ensure a quality of the products created with the method.
According the product the normal heavy-water, magnetically treated heavy-water enriched with medical oxygen gas while passing through a magnetic field, was used in preparing a nutritional solution capable of sustaining added to the water amino acid, vitamins, salts. During the tests we examined the multiplication of mice fibroblast cells in different solution. In the laboratory tests we followed and proved that the growth of cell number is significantly lower in the magnetically treated heavy-water/30 ppm deuterium content/,that was enriched medical oxygen gas while passing through a magnetic field.
The speed of cell multiplication dropped in the magnetically treated heavy-water solution that with enriched with medical oxygen gas/10mg/liter/ while passing through a magnetic field. In contrast, in a normal drinking water and normal heavy-water faster cell multiplication was observed.
COMPERATIVE TABLE 2. Mice fibroblast cell line tissue culture:
Cell number
0 hour 20 hour
Normal drinking water 352 512
Oxygenated drinking water 352 510
Normal heavy-water 352 389
Magnetically treated heavy-water, 352 324 enriched medical oxygen gas/10mg/liter/
COMPARATIVE TABLE 3.
Trough in-vivo tests we examined whether the growth of tumor was influenced by making the mice drink:
1., Magnetically treated heavy-water/30 ppm deuterium content/, enriched with medical oxygen gas lOmg/liter while passing through a magnetic field./Group A/
2. Normal heavy-water/30 PPM deuterium content. /Group B/
3. In the control group we gave the mice normal drinking water. /Group C/
In the laboratory tests series according to the procedure, we transplanted tumors into the mice.
Tumor types.
MCF-4 human breast tumor
PC-2 human prostate tumor
HT-27 colon tumor
The formerly known effects of magnetically heavy-water/30 ppm deuterium content/ on cancerous diseases was brought to an optimal level when we enriched it with medical oxygen gas while passing through a magnetic field.
The result:
MCF-4 cell line
In the A group that drank the magnetically treated heavy-water/30 ppm deuterium content/, enriched medical oxygen gas lOmg/liter, while passing through a magnetic field: 14 animals surveyed, in 8 animals the tumor disappeared in 90 days.
In the B group that drank the normal heavy-water/30 ppm deuterium content/ in animal 8 animal survived, in 13 animals of died in 90 days.
In the C group that drank normal drinking water, 17 animals out of died 5 animals survived in 90 days.
PC-2 cell line
In the A group out of the magnetically treated heavy-water/30 ppm deuterium content/, enriched medical oxygen gas lOmg/liter, while passing through a magnetic field 13 animals survived, in 7 animals the tumor disappeared, 2 animals died in 90 days.
In the B group that drank normal heavy-water/30 ppm deuterium content/in 7 animal survived, 5 animals the tumor disappeared and 10 animal died in 90 days.
In the group C that drank normal drinking water, 18 animals out of died and 4 animals the tumor disappeared.
HT-27 cell lines
In the A group magnetically treated heavy-water/30 ppm deuterium content/, enriched medical oxygen gas, 10 mg/liter while passing through a magnetic field in 14 survived, 8 animals out of died in 90 days.
In the group B that drank normal heavy-water/30 ppm deuterium content/ in 9 survived, 13 animals out of died in 90 days.
In the group C that drank normal drinking water, 19 animals out of died and 3 animals the tumor disappeared.
Tests on animals showed that fatality was lower in the group treated with magnetically treated heavy-water/30 ppm deuterium content/, enriched with medical oxygen gas while flown through a magnetic field than it was in the control group.
The body/tumor mass of the mice was similar to that of starting treatment of a human with a body mass of 80 kg and tumor mass of 2 kg. /
In infusion solutions the daily dose can be of 2-4 liter. Since the magnetically treated heavy- water/30 ppm deuterium content/, enriched with medical oxygen gas while run through a magnetic field does not contain minerals, it has to be given additives before human consumption. The ideal salt concentration per liter: Na: 90 mg, K: 150 mg, Ca: 130 mg, Mg: 70 mg, Cl: 500 mg.
According to product the magnetically treated heavy- water /30 ppm deuterium content with" medical oxygen gas enriched while passing through a magnetic field, enhances the influence on the body and stops the multiplication of cancerous cells, we supply reduced energy level of hydrogen, with magnetic bioenergy.
The furthermore basic of this invention is the understanding cancer comparison with AIDS/HIN-
1/ diseases. According to available literature product through oxygen enrichment within a magnetic field has not been known in anti-ALDS/HIN-1/ products.
According to the procedure of AIDS/HIN-l virus/cells, we get magnetically treated heavy-water
0,1-120 ppm deuterium content, enriched with medical oxygen gas within a magnetic field.
Comparative table 4.
Positive effect have been proved in in- vitro" ALDS test with HIN-1 virus.
„A" control liquid was normal drinking water. Mineral salts contain/1 litre: Νa-lOOOmg, K-
200mg, Ca-160mg, Mg-88mg, and Cl-600mg.
„B" treated liquid was magnetically treated-heavy water 30 ppm deuterium concentration/1 liter, that was enriched medical oxygen gas lOmg/liter while passing through a magnetic field.
"C" liquid was normal heavy-water 30 ppm deuterium contain.
Added to heavy-water solutions vitamins. Vitamin contain/litre: lOOmg of sodium, 150mg of calcium, and 80mg of magnesium, 500mg of chlorine, and 150mg of potassium.
O hour 24 hour
Cell number
„A" liquid 300 510
„B" liquid 300 370
"C" liquid 300 450
SUMMARY: The „B" liquid effectively stops, the multiplication of HIN-1 virus cells. In contrast in normal drinking water and normal heavy- water a faster cell multiplication was observed.
The subject of invention importance of enriching magnetically treated heavy water /30 ppm deuterium content/ with medical oxygen gas, within a magnetic field.
Professor Albert Szent-Gyδrgyi, a Νobel Prize laureate, had called into attention in 1978 that a magnetic field can transform a liquid into an orderly, optimal physical structure. Such "orderly water" makes up somewhat more than one half of the living organism. If the organization of water decreases, the tissues disintegrate; the cells separate from one another. In the intercellular space water is the media of exchanging information.
There is always a sphere of 10-20 water molecules around each protein has an orderly structure in each instance.
Magnetically treated water and heavy-water similarly to enzymes, facilitates rapid charge transfer. It becomes bio-energetically active; we ensure energetically levels of the water:
Comparative table 5. Dielectric constant
Water: 81,5 εr, oxygenated,/10mg per litre/drinking water is 82,6 εr Normal heavy-water /30 ppm deuterium content /82,4 εr Oxygenated/lOmg/liter/ within a magnetic field heavy-water, 30 ppm deuterium content: 83,3 εr
Surface tension
Water: 7,40 x 10 Nm, Oxygenated/1 Omg per litre/drinking water: 7,50 x 10 Nm, Normal heavy- water/30 ppm deuterium content: 7,50 x 10 Nm, Oxygenated/ 1 Omg per litre/within a magnetic field heavy-water, 30 ppm deuterium content: 7,70 x 10 Nm
Viscosity
Water: 1,03 x 10 Pa.sec,Oxygenated/10mg per litre/drinking water: 1,03 x 10 Pa.sec, Normal heavy-water/30 ppm deuterium content: 1,04 x 10 Pa.sec, Oxygenated/1 Omg/liter/wi thin a magnetic field heavy-water, 30 ppm deuterium content: 1,06 x 10 Pa.sec
Conductivity
Water:5,90 x 10 mS,Oxygenated/10mg per litre/drinking water:5,90 x 10 mS ,Normal heavy- water/30 ppm deuterium content:6,39 x 10 mS, Oxygenated 10 mg per litre/within a magnetic field heavy-water,30ppm deuterium content:8,30 x 10 Ms
On the inner and outer cellmembrane, due to ion difference, an electric duality starts out. The electrostatic effects of this electric duality has its effects on the cells as well as on the intercellular entities. Mitochondrion utilizes magnetic spatial energy. All processes within a living organism are regulated by very weak magneto-gravitational forces. It is obvious that without special energy protection the living matter could not survive.
When a cell starts multiplying, actually the long-term order ceases to exist. Its connection with other cells becomes loose. Cell multiplication requires the alteration of the water structure of the cell. The water structure around the cell becomes disorganized.
If the orderly structure of cells is not restored by the end of cell multiplication, a pathological change or even cancerous disease can start out. Since the amorphous structure of the water sphere is responsible for the formulation of cancer, every alteration in the water sphere of cells, that is, cell isolation is a source of dangers. The subject of invention important point, we must supply the reduced energy of hydrogen with magnetic bioenergy.
To reestablish the orderly structure in case of cancerous and HIN-1 cells we get magnetically treated heavy-water/30 ppm deuterium content/ enriched with medical oxygen gas lOmg/liter within a magnetic field to the immediate area of the cancerous and HIN-1 cell or cell group, that stops cancerous and HIN-1 cell multiplication, provides magnetic energy/bio energy/, reestablishes of the orderly water structure of the cell. Through oxygen intake we can improve the breathing of the cells in the body with which its immune capacities are raised. Through oxidation processes poisonous materials decrease. It has positive effect on the through-flow capacity of capillary vessels. By replenishing oxygen within a magnetic field, we can decrease the carcinogenic effect. The basic purpose of invention is create an effective anti -cancer, bio- medical product and manufacturing bitechnology.
Some examples to the possible application of invention,not limited to any or all possiblites protected by the claimed patent.
Example 1
Producing magnetically treated liquid product, enriched with medical oxygen gas, within a magnetic field.
Normal drinldng water is enriched with medical oxygen gas at a oxygen-enriched apparatus
(Figure 1): inflow section 1 as a valve is opened, drinking water is flown through a magnetic apparatus and is directly enriched with oxygen gas in to the direct connection to the magnet 2, the magnet 3 increase oxygen concentration level, water is flown through a magnetic cylinder 4 and blending with oxygen, water out flow in the out flow section 5.
The optimum amount medical oxygen gas issued/enriched/ is 10-20mg/liter.
Example 2
The use of water enriched with medical oxygen gas within a magnetic field in producing soft drinks, beverages.
Normal drinking water made according to the methods explained in example 1 can further be used advantageously to produce soft drinks by adding drink concentrates.
Composition :50g/li ter sugar,5 volume% orange juice, 10-20mg/liter medical oxygen gas, lg/liter citric acid,500mg/liter natural aromas.
Example 3
Producing magnetically treated heavy- water product,introduced directly enriched with medical oxygen gas, within a magnetic field.
Heavy water treating made according to the methods explained in example 1, and the characteristic with the following steps:
Basic substance heavy-water /0, 1-111 ppm deuterium content/manufacturing, by isotopic exchange between water and H2S occurring upon temperatures difference or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, after direct enriched with medical oxygen gas 10-20mg/liter while passing through a magnetic field. The resulting magnetically treated heavy water has been transformed into a medical liquid within the magnetic field and the outflow liquid bottling in the bottles.
Claims
The embodiments of the invention in which an exclusive property or privilege is claimed as follows: l.,The procedure of producing Goldaqua, oxygen-enriched within a magnetic field magnetically treated water food-bio products and oxygen-enriched within a magnetic field magnetically treated heavy-water/0, 1-120 ppm deuterium content/pharmaceutical liquid products, suitable to prevent and cure cancerous and AIDS/ΗIN-1/ diseases, these liquids is direct enriched with medical oxygen gas, within a magnetic field, at the a gas, mostly oxygen gas-enriched apparatus for preparing these product, that have a parts inflow section III, direct connection in to the magnet/2/, magnet/3/,magnetic cylinder /4/,outflow section/5/, with that characteristic, direct connection in to the magnet/2/with directly untie bond through at the magnet/3/connecting in to the inflow section/1/, that have a place between inflow section 111 and outflow section/5/,and formed magnetic cylinder/4/ with thread of scream inflow section/1/ and the magnetic cilynder/4/ strength of the magnetic field is optimal level is 1000-1500 gauss, the type of magnet used is Ferrite magnet.
2., Oxygen enrichment apparatus for oxygen enrichment within a magnetic field as claimed claim l.that characteristic with the used different magnet types, different strength of the magnetic energy levels.
3., The procedure of producing oxygen-enriched within a magnetic field for preparing products as claimed in claim 1, that characteristic comprising the steps, with the basic heavy-water manufacturing process producing by isotopic exchange between water and H2S occurring upon temperatures difference or magnetically treated water in a fractionating with rectifiler, of 10-29 plates, under pressure of 20-30 millibar and at a temperature of 40 Celsius, water and/or aqueous solution having a /0, 1-120 ppm deuterium content /for preventing and curing cancerous and AIDS/HIN-1/ diseases.
4., The procedure of producing food and medical products ,oxygen-enriched within a magnetic field magnetically treated water and heavy-water as claimed in claim 1, that characteristic is transformed into beverages standard food industry additives and aromas are added to the liquid products.
5., The object of the invention is to further more pharmaceutical products with heavy-water as claimed in claim 3, that characteristic in which the product is formulated in the form of indictable solution, infusion solution,medicinal solutions.
6., Procedure of producing oxygen-enriched within a magnetic field, with the characteristic as claimed in claim 1, that characteristic a long term guaranteed lasting of the magnetic-energy liquids and to this food-medical manufacturing biotechnology.
7., Use of oxygen-enriched within a magnetic field heavy-water as claimed in patent claim 3, that characteristic magnetically treated heavy-water /0,1-120 ppm deuterium content/ aqueous solutions to prevent or cure tumors and AIDS/HIN-1/ diseases.
8., Use of heavy-water food-medical solutions with that characteristic manufacturing process producing by isotopic exchange between water and H2S occurring upon temperatures difference.
9., The object of invention further more is pharmaceutical products , too.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU2002/000085 WO2004022098A1 (en) | 2002-09-09 | 2002-09-09 | Oxygen-enriched water, treated within a magnetic field and heavy water |
| AU2002321678A AU2002321678A1 (en) | 2002-09-09 | 2002-09-09 | Oxygen-enriched water, treated within a magnetic field and heavy water |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU2002/000085 WO2004022098A1 (en) | 2002-09-09 | 2002-09-09 | Oxygen-enriched water, treated within a magnetic field and heavy water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004022098A1 true WO2004022098A1 (en) | 2004-03-18 |
Family
ID=31972009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU2002/000085 WO2004022098A1 (en) | 2002-09-09 | 2002-09-09 | Oxygen-enriched water, treated within a magnetic field and heavy water |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002321678A1 (en) |
| WO (1) | WO2004022098A1 (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2215260A1 (en) * | 2007-10-25 | 2010-08-11 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| EP2214712A1 (en) * | 2007-10-25 | 2010-08-11 | Revalesio Corporation | Compositions and methods for treating asthma and lung disorders |
| EP2282719A2 (en) * | 2008-04-28 | 2011-02-16 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| EP2347662A2 (en) * | 2008-11-13 | 2011-07-27 | Comercializadora S. Car Borr, S.A. de C.V. | Kit of pharmaceutical formulations characterised by the presence of molecular oxygen |
| EP2350263A1 (en) * | 2008-10-22 | 2011-08-03 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| US8962700B2 (en) | 2006-10-25 | 2015-02-24 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| US9011922B2 (en) | 2009-04-27 | 2015-04-21 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US9034195B2 (en) | 1997-10-24 | 2015-05-19 | Revalesio Corporation | Diffuser/emulsifier for aquaculture applications |
| US9198929B2 (en) | 2010-05-07 | 2015-12-01 | Revalesio Corporation | Compositions and methods for enhancing physiological performance and recovery time |
| US9402803B2 (en) | 2006-10-25 | 2016-08-02 | Revalesio Corporation | Methods of wound care and treatment |
| US9492404B2 (en) | 2010-08-12 | 2016-11-15 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
| US9512398B2 (en) | 2006-10-25 | 2016-12-06 | Revalesio Corporation | Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3431080A (en) * | 1963-11-15 | 1969-03-04 | Commissariat Energie Atomique | Apparatus for the production of heavy water |
| EP0322544A1 (en) * | 1987-12-29 | 1989-07-05 | Emil Schaerer & Co. | Drinking-water magnetizing device |
| EP0409491A2 (en) * | 1989-07-17 | 1991-01-23 | Elir Advanced Technology Ltd. | Magnetic treatment of water used for agricultural purposes |
| WO1995018545A1 (en) * | 1994-01-06 | 1995-07-13 | Hyd Kutató-Fejlesztó Ktf. | Food products for preventing development of diseases and process for preparing same |
| US5855921A (en) * | 1991-10-31 | 1999-01-05 | Somlyai; Gabor | Pharmaceutical products for curing tumorous diseases and process for preparing same |
| US6361810B1 (en) * | 1997-10-23 | 2002-03-26 | Eco Naturforschungs-Und Technologie Gesellschaft Mbh | Method for improving the biological properties of aqueous liquids and edible oils and for improving combustion |
-
2002
- 2002-09-09 AU AU2002321678A patent/AU2002321678A1/en not_active Abandoned
- 2002-09-09 WO PCT/HU2002/000085 patent/WO2004022098A1/en not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3431080A (en) * | 1963-11-15 | 1969-03-04 | Commissariat Energie Atomique | Apparatus for the production of heavy water |
| EP0322544A1 (en) * | 1987-12-29 | 1989-07-05 | Emil Schaerer & Co. | Drinking-water magnetizing device |
| EP0409491A2 (en) * | 1989-07-17 | 1991-01-23 | Elir Advanced Technology Ltd. | Magnetic treatment of water used for agricultural purposes |
| US5855921A (en) * | 1991-10-31 | 1999-01-05 | Somlyai; Gabor | Pharmaceutical products for curing tumorous diseases and process for preparing same |
| WO1995018545A1 (en) * | 1994-01-06 | 1995-07-13 | Hyd Kutató-Fejlesztó Ktf. | Food products for preventing development of diseases and process for preparing same |
| US6361810B1 (en) * | 1997-10-23 | 2002-03-26 | Eco Naturforschungs-Und Technologie Gesellschaft Mbh | Method for improving the biological properties of aqueous liquids and edible oils and for improving combustion |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034195B2 (en) | 1997-10-24 | 2015-05-19 | Revalesio Corporation | Diffuser/emulsifier for aquaculture applications |
| US9512398B2 (en) | 2006-10-25 | 2016-12-06 | Revalesio Corporation | Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles |
| US9402803B2 (en) | 2006-10-25 | 2016-08-02 | Revalesio Corporation | Methods of wound care and treatment |
| US9004743B2 (en) | 2006-10-25 | 2015-04-14 | Revalesio Corporation | Mixing device for creating an output mixture by mixing a first material and a second material |
| US8962700B2 (en) | 2006-10-25 | 2015-02-24 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| US9511333B2 (en) | 2006-10-25 | 2016-12-06 | Revalesio Corporation | Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| EP2214712A4 (en) * | 2007-10-25 | 2013-02-27 | Revalesio Corp | Compositions and methods for treating asthma and lung disorders |
| EP2215260A1 (en) * | 2007-10-25 | 2010-08-11 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| EP2214712A1 (en) * | 2007-10-25 | 2010-08-11 | Revalesio Corporation | Compositions and methods for treating asthma and lung disorders |
| AU2008316794B2 (en) * | 2007-10-25 | 2015-04-23 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| EP2282719A4 (en) * | 2008-04-28 | 2011-11-09 | Revalesio Corp | Compositions and methods for treating multiple sclerosis |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| EP2282719A2 (en) * | 2008-04-28 | 2011-02-16 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| EP2364154A1 (en) * | 2008-10-22 | 2011-09-14 | Revalesio Corporation | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| EP2364154A4 (en) * | 2008-10-22 | 2013-07-10 | Revalesio Corp | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| EP2350263A4 (en) * | 2008-10-22 | 2013-07-03 | Revalesio Corp | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| EP2350263A1 (en) * | 2008-10-22 | 2011-08-03 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| EP2347662A4 (en) * | 2008-11-13 | 2012-11-28 | Com Izadora S Car Borr S A De C V | Kit of pharmaceutical formulations characterised by the presence of molecular oxygen |
| EP2347662A2 (en) * | 2008-11-13 | 2011-07-27 | Comercializadora S. Car Borr, S.A. de C.V. | Kit of pharmaceutical formulations characterised by the presence of molecular oxygen |
| US9272000B2 (en) | 2009-04-27 | 2016-03-01 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US9011922B2 (en) | 2009-04-27 | 2015-04-21 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US9198929B2 (en) | 2010-05-07 | 2015-12-01 | Revalesio Corporation | Compositions and methods for enhancing physiological performance and recovery time |
| US9492404B2 (en) | 2010-08-12 | 2016-11-15 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002321678A1 (en) | 2004-03-29 |
| AU2002321678A8 (en) | 2004-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004022098A1 (en) | Oxygen-enriched water, treated within a magnetic field and heavy water | |
| Qin et al. | In vitro antioxidant activity and in vivo antifatigue effect of layered double hydroxide nanoparticles as delivery vehicles for folic acid | |
| Marshall | Lithium as a nutrient | |
| CN105476020B (en) | A kind of vitamin D3Soft capsule and preparation method thereof | |
| EP3260421A1 (en) | Composite mineralized ceramic material capable of producing active hydrogen healthcare water | |
| US20050260277A1 (en) | Method and formula for anti-tumor and anti-matastatic effect | |
| EP3313448A1 (en) | A highly concentrated seawater mineral extract and uses thereof | |
| Sircus | Transdermal Magnesium Therapy: A New Modality for the Maintenance of Health | |
| CN109965166A (en) | A kind of production method of lentinan drink | |
| TW201330847A (en) | Composition for preventing and treating cancer and method for manufacturing the same | |
| CA2296822A1 (en) | Goldaqua, oxygen-enriched within a magnetic field, magnetically treated water and heavy water/0.1-111 ppm deuterium content/, food-bio and pharmaceutical liquid product, suitable to prevent and cure cancereus and aids diseases and apparatus for preparing these product. | |
| KR100943204B1 (en) | Functional drinking water for the blood circulation improvement and preparation method thereof | |
| CN1415241A (en) | Nano selenium of glucomannan and its preparation method | |
| CN106466328A (en) | Deep sea water extract and its use | |
| CN1415308A (en) | Nano selenium of amino acid and its preparation method | |
| CN109043224A (en) | A kind of cleanser reducing cadmium enrichment in edible shellfish body | |
| CN108936622A (en) | Double protein intestinal cancer nutraceutical and preparation method thereof | |
| Abdullajonovna | INTERACTION BETWEEN DRUG SUBSTANCES AND NUTRIENT PRODUCTS | |
| CN108402470A (en) | A kind of nutrition fortifier and its beverage and preparation method of supplement zinc selenium rubidium | |
| Tan et al. | The formation of egg white polypeptide‐selenium complex particles: mechanism, stability and functional properties | |
| CN101040875A (en) | Physiology injection liquid of deep seawater | |
| CN1181076C (en) | Trace element-vitamine compound and its preparing process and application | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| TW201741252A (en) | Composite mineralized-ceramic material | |
| WO2014138722A1 (en) | Process for the preparation of a non-corrosive base solution and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CH CN CZ DE DK EE ES FI GB GE JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |